Related Experiment Video

Updated: Dec 14, 2025

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.1K

Depatux-M and temozolomide in advanced high-grade glioma

Sophie Hirsch1,2,3,4, Cristiana Roggia5, Saskia Biskup6

  • 1Department of Neurology and Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany.

Neuro-Oncology Advances
|July 25, 2020
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.7K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.9K

Related Experiment Videos

Last Updated: Dec 14, 2025

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.1K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.7K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.9K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K

Articles linked to this work by shared authors, journal, and citation graph.

Correlation of [18F]SiTATE-PET-tracer with somatostatin receptor expression in meningiomas: an exploratory ex vivo histological pilot study.

EJNMMI research·2026

9.4-Tesla magnetic resonance imaging in focal epilepsy patients with high-resolution surface-based profiling of focal cortical dysplasias.

Epilepsia·2026

Cerebral gray matter volumes in long-term post-COVID patients are associated with peripheral kynurenine pathway metabolites and the severity of depressive symptoms.

Brain, behavior, and immunity·2026

IV Thrombolysis Before Thrombectomy in Carotid Artery Dissection-Related Large-Vessel Occlusion.

Neurology·2026

A Severity-Agnostic Atrophy Pattern in Spinocerebellar Ataxia Type 3: Volumetrics from ENIGMA-Ataxia.

Movement disorders : official journal of the Movement Disorder Society·2026

Automated Deep Learning-Based Demyelination Load Segmentation in Metachromatic Leukodystrophy.

Clinical neuroradiology·2026

[18F]FET PET imaging for early response assessment of bevacizumab in recurrent glioblastoma.

Neuro-oncology advances·2026

A novel approach to reverse Warburg metabolism in patients with recurrent glioblastoma: A phase II pharmacodynamic study of dichloroacetate.

Neuro-oncology advances·2026

Correction to: Exploring relationships between abnormal within-network functional connectivity, preoperative brain tumor variables, and neuropsychological test scores.

Neuro-oncology advances·2026

Combination of EZH2 and MEK inhibitors as an effective therapy for neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.

Neuro-oncology advances·2026

Perineuronal net degradation in aggressive glioblastomas with KANK1::NTRK2 fusions.

Neuro-oncology advances·2026

Pattern of care and treatment outcome of high-grade glioma patients at 4 Ethiopian teaching hospitals: a prospective cohort study.

Neuro-oncology advances·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us